Refining And Testing A Promising New Treatment For Chronic Pain.
Funder
National Health and Medical Research Council
Funding Amount
$743,947.00
Summary
Chronic pain costs Australia about 35 billion dollars a year. Recent scientific discoveries show that treatment aimed at correcting problems in how the brain processes sensory input can reduce pain and disability. This project will clarify some key aspects of these problems and use that information to make final adjustments to an already very promising treatment. We will then test the treatment in a definitive and comprehensive clinical trial.
Understanding Persistent Low Back Pain Where It Resides, In The Brain
Funder
National Health and Medical Research Council
Funding Amount
$848,972.00
Summary
Low back pain is a leading cause of disability amongst Australians. A critical question is why some people get better after hurting their back while others do not. This project examines whether changes in the brain predict low back pain outcome. This information will rapidly advance our understanding of low back pain and has the potential to facilitate the development of novel therapies.
Neuropathic pain is particularly difficult to treat and existing medications have considerable side effects. This project will develop a new set of glycine transport inhibitors that have the potential to provide pain relief without side effects.
The First Placebo-controlled Trial Of Opioid Analgesics For Acute Spinal Pain
Funder
National Health and Medical Research Council
Funding Amount
$1,024,067.00
Summary
Despite the widespread and increasing use of opioid analgesics, there is a complete lack of evidence on their efficacy in acute spinal pain. Concerns are also being raised because of the risks of potentially serious adverse events associated with opioid analgesics. In this world-first study, we will establish whether using opioid analgesics can effective reduce pain in people with acute spinal pain and provide rigorous evidence to inform the safe and appropriate use of this medicine.
Resolve: A New Treatment - Sensorimotor Retaining With Explaining Pain - For Chronic Low Back Pain.
Funder
National Health and Medical Research Council
Funding Amount
$1,005,534.00
Summary
Most treatments for low back pain that are provided by a GP, physiotherapist or chiropractor are only moderately effective. A new approach is needed. We have developed a new treatment, sensorimotor retraining, based on principles from neuroscience, education, psychology and physiotherapy that we are testing in a randomized controlled trial. If successful this new treatment will provide relief for the millions of Australians who suffer from this debilitating condition.
Pregabalin In Addition To Usual Care For Sciatica (PRECISE): A Randomised, Placebo-controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$638,663.00
Summary
Sciatica is a severe and disabling form of back pain that is characterised by radiating pain down the leg. However there is little evidence on how best to treat it conservatively. We propose to investigate the effectiveness of pregabalin, a medication that specifically targets sciatic pain, in addition to usual care in 204 patients with sciatica. We hypothesise that adding pregabalin will be more effective in reducing the severity of leg pain.
Spinal Cord Injury Pain: Understanding Mechanisms To Develop Treatments
Funder
National Health and Medical Research Council
Funding Amount
$597,675.00
Summary
Spinal cord injury has devastating effects on health and quality of life. Many of the major consequences of injury, such as chronic pain and loss of voluntary voiding, are "invisible" – i.e., they are not as visible as limitations of mobility. Our study aims to define the neurobiological changes that cause development of persistent pain after spinal cord injury and use pharmacological tools to attenuate the development of pain.
Combating Escalating Harms Associated With Pharmaceutical Opioid Use
Funder
National Health and Medical Research Council
Funding Amount
$925,767.00
Summary
Increases in opioid use have been accompanied by increased opioid harms. But there is a lack of population-level evidence about drivers of long-term prescribed opioid use, dependence, overdose and other harms. Using linked data, we will fill these gaps using a cohort of all people in NSW prescribed opioids since 2002, linked to datasets containing information on health, social and health service utilisation, that will permit a comprehensive assessment of the risks of all prescribed opioids.
Pharmaceutical Opioids For Chronic Non-cancer Pain: Evaluating Health Outcomes And Economic Impact Over Five Years
Funder
National Health and Medical Research Council
Funding Amount
$775,922.00
Summary
Chronic non-cancer pain (CNCP) is a major contributor to disability. Increased opioid prescribing for CNCP has produced concern about dependence and overdose in the absence on data on its long-term effectiveness. Novel statistical methods will test causal relationships over 5 years between treatment, outcomes, and costs on 1,514 CNCP patients prescribed opioids. We will answer critical questions on 5-year outcomes, and whether, and for whom, opioids and other clinical interventions reduce costs.
Eighty percent of adults will suffer back pain at some time during their life. More than one in three will develop chronic back pain and cost Australia about $9 billion per year. We can now identify those who will develop chronic back pain early. This project will test a new method of treating these people who are risk of chronic back pain. We predict that our short and targeted intervention will stop these people from developing of chronic back pain and this will lead to massive savings to the ....Eighty percent of adults will suffer back pain at some time during their life. More than one in three will develop chronic back pain and cost Australia about $9 billion per year. We can now identify those who will develop chronic back pain early. This project will test a new method of treating these people who are risk of chronic back pain. We predict that our short and targeted intervention will stop these people from developing of chronic back pain and this will lead to massive savings to the Australian communityRead moreRead less